Abstract | Objectives: The aim of this study is to determine serum adropin levels in patients with heart failure in comparison with healthy controls.
Patients and methods: This study enrolled a total of 30 heart failure patients and 30 healthy control subjects. The heart failure patients were evaluated in the first 24 hours of hospital admission. Evaluation included physical examination, medical history, venous blood sampling, blood pressure measurement, and transthoracic echocardiography (TTE). American Society of Echocardiography (ASE) guidelines were used for TTE examination. Laboratory analyses of collected venous blood samples was performed at Department of Medical Laboratory Diagnostics by experienced biochemist that was blinded to subject group assignment. Serum adropin levels were determined with dual enzyme-linked immunosorbent assay (ELISA) (Phoenix Pharmaceuticals, Burlingame, USA).
Results: Patients with heart failure had significantly higher serum levels of adropin compared to the control group (7.1 ± 0.56 vs 4.23 ± 0.31 ng/mL, P<0.001). We found a positive correlation between serum adropin and NYHA score (r = 0.389, P=0.002), NT-proBNP (r = 0.393, P=0.001) and BMI (r = 0.256, P=0.035). A negative correlation was found between serum adropin and LVEF (r = -0.325, P=0.011) and CRP (r = -0.259, P=0.045).
Conclusions: Serum adropin is significantly increased in people with heart failure compared to the control group which implies possible involvement of adropin in heart failure pathophysiology. However, future larger multicentric studies are needed to address these findings. |
Abstract (croatian) | Ciljevi: Cilj ovog istraživanja je utvrditi razinu adropina u serumu u bolesnika sa zatajenjem srca i usporediti je s razinom adropina u serumu zdravih kontrolnih ispitanika.
Metode: Ovo je istraživanje obuhvatilo ukupno 30 bolesnika sa zatajenjem srca i 30 zdravih ispitanika. Bolesnici sa zatajivanjem srca procjenjivani su u prva 24 sata po prijemu u bolnicu. Procjena je uključivala fizikalni pregled, povijest bolesti, uzimanje uzorka venske krvi, mjerenje krvnog tlaka i transtorakalnu ekokatiografiju (TTE). Za ispitivanje TTE korištene su smjernice Američkog društva za ehokardiografiju (ASE). Laboratorijske analize uzetih uzoraka venske krvi napravljene su na Odjelu za medicinsku laboratorijsku dijagnostiku od strane iskusnog biokemičara, koji je bio zaslijepljen za skupine ispitanika. Razine adropina u serumu određene su ELISA metodom (Phoenix Pharmaceuticals, Burlingame, SAD).
Rezultati: Pacijenti sa zatajivanjem srca imali su značajno više razine adropina u serumu u usporedbi s kontrolnom skupinom (7,1 ± 0,56 naprema 4,23 ± 0,31 ng/mL, P <0,001). Analizom je utvrđena pozitivna povezanost između serumskog adropina i NYHA zbira (r = 0,389, P = 0,002), NT-proBNP-a (r = 0,393, P = 0,001) i BMI-a (r = 0,256, P = 0,035). Pronađena je negativna povezanost između serumskog adropina i LVEF-a (r = -0,325, P = 0,011) i CRP (r = -0,259, P = 0,045).
Zaključak: Serumski adropin je značajno povišen u bolesnika sa zatajenjem srca u odnosu na kontrolnu skupinu, što implicira moguću uključenost adropina u patofiziologiju zatajenja srca. Međutim, potrebne su buduća veća multicentrična ispitivanja kako bi se razjasnili ovi nalazi. |